Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Net Income (2020 - 2025)

Historic Net Income for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$24.3 million.

  • Janux Therapeutics' Net Income rose 1335.04% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 6832.13%. This contributed to the annual value of -$69.0 million for FY2024, which is 1835.73% down from last year.
  • Latest data reveals that Janux Therapeutics reported Net Income of -$24.3 million as of Q3 2025, which was up 1335.04% from -$33.9 million recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Net Income peaked at -$2.3 million during Q1 2021, and registered a low of -$33.9 million during Q2 2025.
  • In the last 5 years, Janux Therapeutics' Net Income had a median value of -$16.1 million in 2022 and averaged -$16.0 million.
  • As far as peak fluctuations go, Janux Therapeutics' Net Income plummeted by 75716.56% in 2021, and later surged by 6596.41% in 2024.
  • Quarter analysis of 5 years shows Janux Therapeutics' Net Income stood at -$13.4 million in 2021, then fell by 19.75% to -$16.1 million in 2022, then grew by 26.81% to -$11.8 million in 2023, then tumbled by 71.93% to -$20.2 million in 2024, then dropped by 20.27% to -$24.3 million in 2025.
  • Its Net Income stands at -$24.3 million for Q3 2025, versus -$33.9 million for Q2 2025 and -$23.5 million for Q1 2025.